Greer Capital Advisors

ViroXis Corporation is a bio-pharmaceutical company based in San Antonio, Texas, specializing in the development and commercialization of botanical pharmaceuticals derived from East Indian sandalwood oil. The company has developed a proprietary botanical ointment that utilizes a defined mixture from Santalum album, aimed at treating human papillomavirus (HPV) infections of the skin in both children and adults. Additionally, ViroXis is working on an EISO cream to address other HPV-related conditions. The company has established strategic partnerships with TFS Corporation Ltd. and DPT Laboratories, Inc. Founded in 2006, ViroXis operates as a subsidiary of TFS Corporation Ltd. as of 2015.

PNP Therapeutics is an early-stage, biopharmaceutical company engaged in the development of a platform technology and proprietary products for the treatment of cancer. At the center of PNP's Therapeutic System is a patented enzyme (E. coli purine nucleoside phosphorylase) that has been shown to work with a variety of well-characterized nucleoside prodrugs generating active metabolites with high levels of anti-tumor activity.

TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.